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Abstract
Parasitic helminth neuromuscular function is a proven target for chemotherapeutic control. Although
neuropeptide signalling plays a key role in helminth motor function, it has not yet provided targets for known
anthelmintics. The majority of biologically active neuropeptides display a C-terminal amide (NH2) motif,
generated exclusively by the sequential action of two enzymes, peptidylglycine α-hydroxylating
monooxygenase (PHM) and peptidylglycine α-amidating lyase (PAL). Further to our previous description of
a monofunctional PHM enzyme (SmPHM) from the human blood fluke Schistosoma mansoni, here we
describe a cDNA encoding S. mansoni PAL (SmPAL). SmPAL is a monofunctional enzyme which, following
heterologous expression, we find to have functionally similar catalytic activity and optimal pH values, but key
catalytic core amino acid substitutions, when compared to other known PALs including those found in
humans. We have used in situ hybridisation to demonstrate that in adult schistosomes, SmPAL mRNA (Sm-
pal-1) is expressed in neuronal cell bodies of the central nervous system, consistent with a role for amidated
neuropeptides in S. mansoni neuromuscular function. In order to validate SmPAL as a putative drug target we
applied published RNA interference (RNAi) methods in efforts to trigger knockdown of Sm-pal-1 transcript
in larval schistosomula. Although transcript knockdown was recorded on several occasions, silencing was
variable and inconsistent and did not associate with any observable aberrant phenotype. The inconsistent
outcomes of RNAi suggest that there may be tissue-specific differences in the applicability of RNAi methods
for S. mansoni, with neuronal targets proving more difficult or refractory to knockdown. The key role played by
schistosome amidating enzymes in neuropeptide maturation make them appealing as drug targets; their
validation as such will depend on the development of more robust reverse genetic tools to facilitate efficient
neuronal gene function studies.
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1. Introduction
Diseases caused by helminth parasites remain one of the most significant public health
problems facing society. The most prevalent and chronic flatworm infection of humans,
resulting in a major, poverty-related problem in the developing world is schistosomiasis.
Schistosoma mansoni, designated a Neglected Tropical Disease, is a major cause of human
schistosomiasis, having a global prevalence of over 200 million in an estimated 74
developing countries [1]. The difficult situation facing health organisations involved in the
reduction of morbidity due to schistosomiasis is aggravated by over-reliance on a single
drug, praziquantel (PZQ). Although resistance does not appear to be widespread, it has been
generated in the laboratory [2], and has occurred transiently in field situations [3,4]. These
observations, coupled with increasing distribution and usage of PZQ, provide circumstances
known to foster the development of drug resistance. As a result of this dependence and the
consequent risk of inadvertently selecting for drug-resistant parasites, there is a pressing
need to exploit and develop new drug targets and to develop novel chemotherapeutic agents
for the treatment and control of schistosomiasis [5].
The neuropeptidergic system is central to flatworm motor control - neuropeptide signalling
molecules appear to be involved in the modulation of a range of biological processes
throughout the phylum Platyhelminthes [6–11]. So far, we have identified 18 distinct
amidated peptides in S. mansoni [12,13], several of which have been localised to the CNS
and PNS of larval and adult schistosomes [13–19]. Some of these peptides have also been
shown to exert potent myoexcitatory effects on isolated muscle fibres from adult
schistosomes, and as such are thought to be directly involved in muscle function [20].
Consequently, the neuropeptidergic component of the S. mansoni nervous system represents
an attractive repository of novel drug targets.
The majority of neuropeptides require a carboxy-terminal amide motif to confer biological
activity, as demonstrated by the reduced activity of most non-amidated glycine-extended
precursors (<10 %) in comparison to their α-amidated counterparts [21–24]. Two key
enzymes act sequentially in the only known mechanism for secretory peptide amidation:
peptidylglycine α-hydroxylating monooxygenase (PHM), a copper, oxygen and ascorbate
dependant enzyme which catalyses hydroxylation of the C-terminal glycine present on a
peptide precursor; and peptidylglycine α-amidating lyase (PAL), a zinc dependant enzyme
which catalyses dealkylation of the hydroxylated intermediate to form the α-amidated
neuropeptide and glyoxylate [21,23]. This process occurs throughout the Metazoa, the
importance of which is demonstrated in larval Drosophila melanogaster mutants, where the
deletion of the PHM gene results in embryonic death [25]. In higher organisms PHM and
PAL are commonly encoded by the same transcript, generating a bifunctional protein
designated peptidylglycine α-amidating monooxygenase (PAM) [24]. In stark contrast, the
genomes of a number of invertebrates including the flatworm Dugesia japonica, encode
single copies of monofunctional PHM and PAL [26], while others possess multiple
monofunctional enzymes which can be membrane associated, soluble or even inactive
[24,27]. Crucially, adult S. mansoni express monofunctional PHM (SmPHM), which is
functionally divergent from the mammalian homologue [28]. These organisational and
functional differences between the schistosome and mammalian amidating enzymes
encourage the characterisation of schistosome amidating enzymes and their exploration as
potential drug targets.
Even though neuropeptide signalling is a core component of schistosome neural function
and neuromuscular modulation, it has not been a major focus for novel drug target discovery
and validation in schistosomes, largely hindered by the absence of known neuropeptides and
their cognate receptors. Recent proliferations in EST datasets and publication of the S.
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mansoni genome sequence [29] have fuelled the recent discovery of SmPHM and eighteen
schistosome neuropeptides, making neuropeptide signalling ripe for more detailed
interrogation and validation as a source of suitable targets for schistosome control
[13,28,29]. Further, genome level bioinformatics has uncovered a set of at least 24 putative
schistosome neuropeptide receptors [29], which are appealing because of the proven
druggability of many known G-protein coupled receptors (GPCRs) and their suitability for
high throughput screens. We hypothesise that neuropeptide activation/processing provides
an alternative and potentially powerful set of drug targets. Since the combined activities of
PHM and PAL are the only known conduit to neuropeptide amidation/activation and we
already know schistosomes possess multiple amidated peptide messengers, these enzymes
have much appeal as drug target candidates. Previously we demonstrated that one half of the
neuropeptide amidating pathway in S. mansoni is functionally distinct from that seen in
vertebrates and, indeed, other invertebrates, such that we now switch focus to the second
half of the amidation pathway, PAL. Here we report the identification, localization, cloning
and functional characterisation of a S. mansoni cDNA encoding a novel, monofunctional
PAL enzyme. Further, we attempt to validate its candidature as a drug target through the
application of RNA interference (RNAi).
2. Materials and methods
2.1. Schistosoma mansoni culture
Schistosome infected mice supplied by Dr Fred Lewis, Biomedical Research Institute,
Rockville MD, USA, were maintained and processed at Iowa State University (ISU). Adult
schistosomes recovered from infected mice were either processed for whole-mount in situ
hybridisation (WISH) experiments as previously described [30], or stored in RNAlater to
allow subsequent RNA extraction, before being shipped to Queen’s University Belfast
(QUB) on dry ice. Schistosomes used in the RNA interference (RNAi) experiments were
maintained at QUB in Biomphalaria glabrata snails; cercariae were shed from infected
snails by photostimulus, and mechanically transformed to schistosomula by vortexing,
schistosome bodies were isolated from tails by centrifugation over a solution of 30% Percoll
in water (500 g for 15 min at 4°C), protocol adapted from [53]. Schistosomula were
maintained in vitro in complete RPMI media [31] containing 20% serum, at 37°C in a 5%
CO2 atmosphere.
2.2. Bioinformatics
BLAST methodology [32] was employed to uncover novel putative PAL encoding
transcripts from S. mansoni EST and genomic datasets. BLASTn and tBLASTn tools were
used at the National Centre for Biotechnology Information (NCBI) BLAST server
(http://blast.ncbi.nlm.nih.gov/Blast) as well as the Schistosoma mansoni genome database,
SmGeneDB (http://www.genedb.org/genedb/smansoni). Searches were performed on the
‘est_others’ database, had an expect value of >1000, and were limited by the query
‘Schistosoma mansoni’. Known PAL genes [25] were used as query sequences. Returns
were translated in all six reading frames (http://www.expasy.org/tools/dna.html), and
examined for both the presence of PAL specific motifs and similarity to other PAL genes/
proteins (http://www.ebi.ac.uk/Tools/InterProScan) [33]. Sequences were also analysed for
the presence of an N-terminal secretory signal peptide, and putative N-glycosylation sites,
using the online SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP/) [34], and NetNGlyc
servers (http://www.cbs.dtu.dk/services/NetNGlyc/) respectively.
2.3. RNA extraction and PCR analyses
Messenger RNA was extracted from between 10–50 mg of S. mansoni tissue using
Dynabeads mRNA Direct™ kit (Invitrogen) according to the manufacturer’s instructions.
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mRNA eluted in Tris-HCl was quantified using a NanoDrop™ 1000 spectrophotometer.
Separate populations of 5′ and 3′ RACE-ready cDNAs were generated using the SMART™
RACE cDNA Amplification kit (Clontech/Takara), using ≥1 μg mRNA per synthesis
according to manufacturer’s instructions. RACE cDNA was stored at −20°C until use.
Gene specific primers (GSP) designed against the putative S. mansoni PAL (SmPAL) ESTs
(GenBank accession numbers AM047261 and AM043268) were used in 50 μl PCR
reactions (94°C for 2 min; 40 cycles of : 94°C 1 min, 55°C 1 min, and 72°C 1 min; 72°C for
7 min) to confirm the presence of SmPAL in the following reaction mixture: 5 μl 10x PCR
buffer (Invitrogen), 3 μl MgCl2 (50 mM, Invitrogen), 1 μl dNTP mix (10 mM, Promega), 1
μl of primer SmPAL-F1 and SmPAL-R1 (20 μM; Table 1), 1 μl cDNA template, 0.3 μl
Platinum® Taq DNA Polymerase (5 U/μl, Invitrogen), and ddH2O to 50 μl. Reaction
products were TOPO-TA cloned (Invitrogen) and at least 3 plasmids were sequence verified.
2.4. Functional SmPAL expression
The SmPAL open reading frame (1236 bp) was PCR-amplified using sense primer SmPAL-
Xba1-F and antisense primer SmPAL-Bgl2-R (see Table 1) incorporating 5′ Xba1 and Bgl2
restriction sites respectively. Products were TOPO-TA cloned (Invitrogen) and sequence
verified. Using Xba1, Bgl2, and pBS.rhodopsin, the rhodopsin tag (11 amino acids) was
appended to the C-terminus of SmPAL. pCIS.SmPAL-rhod was then created using Xba1
and Hpa1. pBS.SmPAL-rhod was used as a template to PCR-amplify SmPAL-rhod without
the native S. mansoni signal peptide (aa 1–18) using primers SmPAL-Nhe1-F and SmPAL-
Hpa1-R (see Table 1). The SmPAL-rhod reaction product was placed after the rat PAM
signal peptide and a poly histidine tag in pCIS.sig-His6 yielding pCIS.sig-His6-SmPAL-
rhod. pCIS.SmPAL-rhod was used in functional expression assays.
2.5. Cell culture, transfection, and PAL enzyme assay
Functional expression and characterisation of SmPAL enzymatic activity were carried out as
described [35]. SmPAL, a control vector encoding cytosolic Enhanced Green Fluorescent
Protein (EGFP; pEGFP-N2, Clontech, Palo Alto, CA, USA), and Drosophila PAL (dPAL2)
[35] were expressed in pEAK RAPID cells (a derivative of hEK-293 cells, Edge
Biosystems, Gaithersburg, MD, USA). Cells were transiently transfected using
Lipofectamine 2000 (2 μg/30 mm well). 24 h after transfection, medium was replaced with
serum-free medium, and the cells were incubated for a further 24 h before cells and spent
media were harvested for analysis.
Cell extracts and spent medium were assayed for catalytic activity and Western blots were
carried out to evaluate secretion efficiency; protease inhibitor cocktail and
phenylmethanesulfonylfluoride (PMSF) were added to cell extracts and to spent medium
prior to analysis. For comparison, cells and spent medium containing expressed dPAL2 [34]
were analysed under the same experimental conditions as SmPAL. pEAK RAPID cells
expressing SmPAL were extracted in a low ionic strength buffer with detergent and protease
inhibitors. Spent medium from pEAK RAPID cells was centrifuged to remove debris. For
Western blot analysis, media were denatured by boiling in Laemmli sample buffer. For
enzyme assays, media were diluted into assay diluents (20 mM Na TES (pH 7.4), 10 mM
mannitol, 1.0 mg/mL bovine serum albumin, and1% Triton X-100) [39].
Aliquots of cell extract and spent medium were fractionated on 4–15% polyacrylamide gels
(Invitrogen), transferred to PVDF membranes and subjected to Western blot analysis using a
monoclonal rhodopsin antibody. Secreted, rhodopsin tagged SmPAL was assessed for
catalytic activity, using 0.5 μM αN-acetyl-Tyr-Val-α-hydroxyglycine (mixed with a trace
amount of [125I]-labelled peptide), prepared using recombinant PHM. SmPAL was diluted
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in 20 mM Na TES (pH 7.4, 100mM Tris, 100mM EDTA and 2% SES), 10 mM mannitol,
1.0 mg/ml bovine serum albumin, and 1% Triton X-100 (Pierce). The reaction volume (40
μl) typically contained 0.4 μl of spent medium (diluted to 5 μl), 100–150 mM Na MES (pH
4.5), 1 mM CdCl2 and 0.05% Thesit (Boehringer Mannheim). The reaction mixture was
incubated for 30 min to 1 h at 37 °C, following which the substrate and product were
separated using ethyl acetate phase separation [39]. SmPAL dependence upon pH was
analysed using the catalytic activity assay conditions described above and altering pH using
150 mM Na MES buffers that ranged in pH from 3.0 to 7.5. In all activity assays and
Western blots, pEGFP-transfected cells were used as a blank.
2.6. Sm-pal-1 probe generation and WISH
Sm-pal-1 WISH probe templates were generated by PCR (94 °C 2 min; 40 cycles of: 94 °C
1 min, 55 °C 1 min, 72 °C 1 min; 72 °C for 7 min) using GSPs flanked by T7 RNA
polymerase promoter sequences (sense labelled T7 template: sense primer SmPAL-ISH-T7-
F1 and antisense primer SmPAL-ISH-R1; antisense T7 labelled template: sense primer
SmPAL-ISH-F2 and antisense primer SmPAL-ISH-T7-R2; see Table 1) in a 50 μl reaction
mixture as described above. Probe templates were cloned into pCR2.1-TOPO and at least 3
plasmids were sequence verified. Sm-pal-1 digoxigenin (DIG)-labelled single stranded RNA
(ssRNA) probes with sense and antisense polarity were generated from their cDNA
templates, and WISH was carried out according to the methods described [30,36].
Hybridised probes were detected with substrate (5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium tablet; BCIP/NBT, Sigma-Aldrich) [30]. Specimens were photographed
using a Leica DFC300FX camera and Leica FW4000 V 1.2 software with a Leica DMR
light microscope.
2.7. dsRNA generation
A 226 bp fragment of Sm-pal-1 was generated by PCR (94 °C 2 min; 40 cycles of: 94 °C 1
min, 55 °C 1 min, 72 °C 1 min; 72 °C for 7 min) using GSP flanked by T7 RNA polymerase
promoter sequences (sense T7 labelled template: sense primer SmPAL-RNAi-T7-F1 and
antisense primer SmPAL-RNAi-R1; antisense T7 labelled template: sense primer SmPAL-
RNAi-F2 and antisense primer SmPAL-RNAi-T7-R2; see Table 1), in a 50 μl reaction
mixture as described above. In addition a 224 bp fragment of the SmPHM transcript [28]
was amplified by PCR (94 °C 2 min; 40 cycles of: 94 °C 1 min, 55 °C 1 min, 72 °C 1 min;
72 °C for 7 min) using GSP flanked by T7 RNA polymerase promoter sequences (sense T7
labelled template: sense primer SmPHM-RNAi-T7-F1 and antisense primer SmPHM-RNAi-
R1; antisense T7 labelled template: sense primer SmPHM-RNAi-F2 and antisense primer
SmPHM-RNAi-T7-R2; see Table 1), in a 50 μl reaction mixture. Sm-phm-1 dsRNA was
used in Sm-pal-1 RNAi experiments as a non-target control dsRNA. Products were TOPO-
TA cloned and at least 3 plasmids were sequence verified. The Sm-pal-1 construct displayed
no similarity to any other S. mansoni sequence as shown by BLASTp and tBLASTn
searches of schistosome sequences on NCBI BLAST server.
Separate populations of ssRNA were generated from T7 labelled templates with sense or
antisense polarity, with the MEGAshortscript™ High Yield Transcription kit (Ambion) at 37
°C for 4 h according to the manufacturer’s instructions. 1 μl of DNase I (New England
Biolabs) was incubated with ssRNA populations at 37 °C for 15 min, equimolar amounts of
sense and antisense ssRNA were mixed and annealed at 75 °C for 5 min and cooled at room
temperature for 30 min to generate dsRNA. 4 μl of RNase If (New England Biolabs) was
added to dsRNA and incubated at 37 °C for 20 min to remove any ssRNA. dsRNA was
recovered by phenol/chloroform extraction and ethanol precipitation, re-suspended in 100 μl
H2O, quantified using the NanoDrop 1000 spectrophotometer, and stored at −80 °C until
use.
Atkinson et al. Page 5
Mol Biochem Parasitol. Author manuscript; available in PMC 2011 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2.8. dsRNA delivery
Sm-pal-1 and Sm-phm-1 dsRNA delivery by electroporation was carried out as described
[37]. 200, 10 day old schistosomula were electroporated in 50 μl of serum-free RPMI culture
medium supplemented with 1 mg/ml Sm-pal-1 dsRNA. During each experiment 200
schistosomula were electroporated in serum-free RPMI without the addition of dsRNA
(−dsRNA), as a negative control. Schistosomula were observed immediately following
electroporation to assess damage, in all cases worms appeared normal following exposure.
Schistosomula were cultured overnight in 100 μl complete RPMI culture medium, which
was replaced with fresh complete RPMI (100 μl) each day for two days after which gene
expression was measured by reverse-transcriptase (RT)-PCR. Schistosomula were observed
once a day, throughout the post-dsRNA delivery culture period, for the appearance of any
aberrant phenotypes associated with altered movement. dsRNA delivery by soaking was
also attempted in this study. Following the 10 day transformation period, approximately 200
schistosomula were transferred into 100 μl of serum-free RPMI supplemented with 0.1 mg/
ml Sm-pal-1 and Sm-phm-1 dsRNA. Each day 50 μl of RPMI was replaced with fresh RPMI
supplemented with 0.1 mg/ml dsRNA. One batch of schistosomula was cultured for the
duration of each soaking experiment in serum-free RPMI in the absence of dsRNA
(−dsRNA), as a negative control. Soaking was originally carried out for 7 days; however, a
high death rate after 5–6 days forced a shorter soaking time such that experiments were
reduced to 5 days. Each day, dsRNA treated and untreated schistosomula were observed
visually for the presence of any aberrant phenotypes, including differences in general
appearance, morphology and movement (number and speed of contractions). After 5 days
gene expression was measured by RT-PCR.
2.9. Reverse-transcriptase PCR (RT-PCR)
mRNA was extracted from schistosomula using Dynabeads mRNA Direct™ kit (Invitrogen)
according to the manufacturer’s instructions. Any remaining DNA was removed by DNase
digestion using DNase I (New England Biolabs), following which the mRNA was purified
using RNeasy Mini Elute Cleanup kit (Qiagen), and quantified using the NanoDrop 1000
spectrophotometer. Specific gene products were amplified from 12 ng of mRNA per RT-
PCR reaction using GSP (Table 1) at a final concentration of 0.6 μM, and the QIAGEN
OneStep RT-PCR kit. In addition to GSPs designed against the experimental target gene Sm-
pal-1, GSPs designed against a 98 bp fragment of the S. mansoni alkaline phosphatase gene
[31], were employed in RT-PCR reactions to enable the comparison of the relative
expression levels of Sm-pal-1 and Sm-ap. Prior to use in RT-PCR reactions, all primer sets
were used in RT-PCR optimisation experiments to ensure that they amplified specific gene
products consistently. Each primer set (SmPAL and SmAP) was used in RT-PCR reactions
on mRNA extracted from schistosomula treated with Sm-pal-1 dsRNA, Sm-phm-1 dsRNA
(non-target control dsRNA) or buffer without dsRNA (negative control). Cycling conditions
were as follows: 50 °C for 30 min, 95 °C for 15 min, followed by 40 cycles of 94 °C 30 sec,
50 °C 45 sec, and 72 °C for 2 min, and a final extension step of 72 °C for 10 min. RT-PCR
products were visualised by agarose gel electrophoresis (as previously described), images
were taken, and transcript abundance quantified relative to standardised DNA size markers
using Quantity One 1-D Analysis software (BioRad).
3. Results
3.1. Identification and characterisation of schistosome PAL (SmPAL)
Interrogation of the schistosome EST database with the Drosophila PAL1 sequence
(GenBank accession number ACJ13179) identified two ESTs encoding a putative SmPAL
(GenBank accession numbers AM047261 and AM043286). Subsequent computational
analysis showed that these ESTs could represent a single SmPAL enzyme with significant
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similarity to the PAL domain of PAM proteins and to monofunctional PAL enzymes.
Highest homology (identified via tBLASTn searches) was to the partial ORF of a putative
Macrostomum lignano PAL (GenBank accession number EG951302, 34.0 % identity).
Primers designed for PCR confirmation of the corresponding full length SmPAL open
reading frame generated a 1236 nucleotide cDNA sequence (GenBank accession number
FJ668386), encoding a 412 amino acid protein. SmPAL has a predicted molecular mass of
48 kDa, and includes an 18 amino acid (aa) signal peptide [38]. The coding sequence of
SmPAL is flanked by a 333 bp 5′ untranslated region (UTR) and a 107 bp 3′ UTR with a
polyadenylation signal (AATATA) 25 bp upstream of the poly(A)+ tail. The sequence of
SmPAL suggests that adult schistosomes express a gene encoding an active monofunctional
PAL enzyme.
A number of amino acids common to all eukaryotic PAL proteins and essential for catalysis
are conserved [39–41] (Fig. 1). The six-bladed β-propeller structure of the rat PAL catalytic
core (rat PALcc) includes a catalytic Zn2+ and a structural Ca2+. The three His residues that
bind the catalytic Zn2+ (His585, His690, His786 in rat PALcc) are conserved, suggesting that
SmPAL and rat PAL may bind Zn2+ in a similar manner. In rat PALcc, the Ca2+ is bound by
two main chain carbonyls (Val520, Leu587) and a carboxylate (Asp787). While Leu587 is
conserved, Val520 is replaced by Ala and Asp787 is replaced by Ser in SmPAL; although the
interactions of Ca2+ with the main chain carbonyls would be conserved in SmPAL, its
interaction with Ca2+ may be altered. The four cysteine residues that form disulfide bonds
positioning key active site residues in rat PALcc are conserved in SmPAL, which has four
additional cysteine residues not common to rat PALcc; three of these additional cysteine
residues are located in what is predicted to form the sixth β-propeller of SmPAL. All of the
key active site residues in rat PALcc (Arg533, Tyr654 and Arg706) are completely conserved
[41].
3.2. Functional analysis of SmPAL
In order to assess the catalytic activity of SmPAL, it was expressed transiently in
mammalian cells. To ensure efficient secretion and detection, the signal sequence of SmPAL
was replaced by the signal sequence of rat PAM; further, an epitope tag (rhodopsin) was
appended to the C-terminus of SmPAL. Drosophila PAL (dPAL2) was previously analyzed
in a similar manner [35] and was expressed at the same time for comparison. Spent medium
and cell extracts were analysed by Western blot, revealing the presence of rhodopsin-tagged
SmPAL in cell extracts and in spent medium (Fig. 2A); transient expression of EGFP served
as a control. While the SmPAL and dPAL2 present in cell extracts were similar in mass (51
kDa), the SmPAL recovered from spent medium was 59 kDa larger than secreted dPAL2.
The predicted mass of His6-SmPAL.rho is 48 kDa, the SmPAL sequence includes four
potential N-linked glycosylation sites (N-X-S/T) (Fig. 1). The potential N-glycosylation
sites closest to the N- and C-termini of SmPAL fall outside of the β-propeller structure
observed for rat PALcc and, therefore, should be accessible to oligosaccharide transferase
[41]; the remaining sites may also be accessible since they would be expected to occur in the
loops connecting the β1/β2 strands of propeller 1 and the β3/β4 strands of propeller 2. The
mass of the rhodopsin-tagged SmPAL protein in cell extracts (51 kDa) makes it unlikely that
more than one or two N-linked oligosaccharide chains are present. The size increase
observed upon secretion of SmPAL suggests the presence of additional modifications such
as the addition of sialic acid residues to N-linked oligosaccharides or O-linked
glycosylation.
Rhodopsin-tagged SmPAL and dPAL2 were both secreted; the amount of medium analyzed
represents the amount secreted in approximately 5 h. Equivalent amounts of cell extract and
spent medium were analyzed for dPAL2 and SmPAL. Since misfolded proteins are not
efficiently secreted, this result indicates that SmPAL, like dPAL2, folds properly in
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mammalian cells. Although SmPAL and dPAL2 were expressed at similar levels (Fig. 2A),
SmPAL was secreted less efficiently. In order to avoid any contribution from newly
synthesized, immature enzyme, activity assays were carried out on spent medium. Cells
transiently expressing EGFP were analyzed as a control and the low level of activity
detected in their medium was subtracted as background. SmPAL enzyme activity was
readily detected in the spent medium (Fig. 2A). The enzymatic activity of recombinant
rhodopsin-tagged dPAL2 was previously characterised [35], and activity was readily
detected in the spent medium. Since both proteins were detected using antibody to
rhodopsin, their specific activities can be compared. Under the assay conditions used, the
specific activity of SmPAL is substantially higher than that of dPAL2.
In mammalian cells, PAL must function in the acidic environment of the secretory granule.
To assess the effect of assay pH on SmPAL activity, aliquots of spent medium from cells
expressing SmPAL were diluted into buffers ranging in pH from 3.5 to 7.5. Optimal activity
was detected at pH 4.5, with a second clear peak of SmPAL activity apparent at pH 6
(Figure 2B). No activity was detectable above pH 7.0. Based on the crystal structure of rat
PALcc, a single residue contacts the amino acid that is to be amidated; the Met784 that
serves this function in rat PALcc is replaced by Asp in SmPAL (Fig. 1). If titration of the
side chain carboxylate affects the binding of substrate to SmPAL, this may explain the
presence of two distinct pH optima.
3.3. Sm-pal-1 transcript expression
Sm-pal-1 in situ hybridisation experiments were carried out on whole mount preparations of
a mixed sex population of adult S. mansoni. Antisense probes were used as experimental
probes to identify the distribution of Sm-pal-1 transcript, visualised by a purple/brown
staining pattern, while sense probes were used in time- and condition-matched experiments
as a negative control. Colour deposition could be visualised within 2 h of incubation with
the BCIP/NBT substrate and continued to develop overnight.
Sm-pal-1 gene expression was localised to neuronal cell bodies in the CNS of adult
schistosomes. Female schistosomes display a marked deposition of Sm-pal-1 staining in the
cerebral ganglia and longitudinal nerve cords of the CNS in the anterior fore-body (Fig. 3A
and B). Transcript localisation is notable in the longitudinal nerve cords surrounding the oral
sucker, and running towards the posterior, parallel to the oesophagus and the bifurcated gut
(Fig. 3A and B). The oesophagus and gut intestinal caecae appear dark brown in colour due
to non-specific interaction of BCIP/NBT with endogenous phosphatses (also evident in
sense-strand treated control worms, where no CNS staining was observed, see Fig. 3). The
longitudinal nerve cords in the mid body of the female worm also demonstrate Sm-pal-1
expression, where they can be seen in close proximity to the uterus (Fig. 3C). Interestingly,
the longitudinal nerve cords display Sm-pal-1 gene expression in a distinct, but increasingly
more diffuse pattern than noted in the bilobed cerebral ganglia. This irregular staining
pattern was also observed in the tail of male worms, where Sm-pal-1 gene expression is
evident in several discrete accumulations of staining (Fig. 3D). There was no evidence of
Sm-pal-1 gene expression in the PNS – likely due to the limited access of antibodies and
staining reagents in the absence of flat-fixing.
Sense probes were employed in negative control experiments to identify any non-specific
staining. Specimens showed no observable staining in control experiments. Note that dark
brown staining of the oesophagus and intestinal caecae was observed in female negative
control specimens as in experimental worms, demonstrating the non-specific staining of
these elements by the BCIP/NBT substrate; no CNS staining was evident (Fig. 3E).
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3.4. Sm-pal-1 RNAi
Following SmPAL dsRNA delivery by electroporation, and 2 day post-dsRNA delivery
schistosomula culture, RT-PCRs revealed no measurable changes in Sm-pal-1 transcript
levels (data not shown). dsRNA delivery by electroporation was attempted twice with two
separate batches of dsRNA, and on both occasions was unsuccessful, thus longer-term
soaking as a means of dsRNA delivery was explored.
In total, six soaking experiments were carried out, of which only two experiments revealed
diminished transcript abundance of Sm-pal-1. In experiments where transcript knock-down
was detected, dsRNA delivery by soaking induced a marked and comparable reduction in
Sm-pal-1 transcript levels as measured by endpoint detection (71–90 %; Fig. 4). Levels of
Sm-pal-1 were unaffected in Sm-phm-1 dsRNA treated worms (Fig. 4). The alkaline
phosphatase control gene Sm-ap showed no measurable difference in expression levels in
dsRNA treated worms (Fig. 4). These observations suggest a specific reduction in the
quantity of Sm-pal-1 transcript. All RT-PCR no template controls were negative.
On each of four further attempts to diminish Sm-pal-1 transcript levels in schistosomula,
RT-PCR did not show any measurable difference in transcript abundance. In all
experiments, whether or not Sm-pal-1 transcript levels were detectably reduced,
schistosomula appeared normal and did not display any observable aberrant phenotypes
from untreated control experiments.
4. Discussion
Carboxy-terminal α-amidation is an essential post-translational modification in the
generation of biologically active neuropeptides. Various studies, involving the amidating
enzymes of eukaryotes, report emerging disparities in amidating enzyme gene organisation
[see 24 for review]. For the most part, PHM and PAL are expressed as separate domains of a
bifunctional PAM protein in higher organisms such as Rattus norvegicus [42], and Xenopus
laevis [43]. In contrast, an increasingly complicated picture of PHM and PAL expression is
emerging from invertebrates, as a number of species including Lymnaea stagnalis [44],
Aplysia californica [45], Calliactis parasitica [46], Drosophila [25,35], Caenorhabditis
elegans [47], and the planarian Dugesia japonica [26] encode single or multiple copies of
one or both enzymes, expressed as bifunctional or monofunctional proteins.
PHM has previously been characterised from S. mansoni and identified as a monofunctional
enzyme [28]. In the same study the use of degenerate primers and BLAST analysis of the
GenBank EST dataset, failed to identify an S. mansoni PAL cDNA [28]. Capitalizing on
more recent S. mansoni EST datasets, we identified a cDNA encoding a monofunctional
schistosome PAL. Interestingly, extended interrogation of schistosome EST and genome
datasets confirmed the absence of an EST representing a bifunctional PAM enzyme in S.
mansoni.
Monofunctional SmPAL is a soluble, secreted enzyme, similar in sequence to other PALs
such as the secreted Drosophila enzyme, dPAL2 [35], retaining four conserved cysteines for
the maintenance of secondary structure, plus four cysteine residues unique to SmPAL, and a
tyrosine residue known to be essential for functionality [39,40]. Yet there are key amino
acid substitutions in SmPAL, in the Ca2+ binding site, and where the amino acid preceding
the α-hydroxyglycine and the PAL active site interact, which set it apart from the host
enzyme. The latter of the two appears particularly significant as it is the Met784 in rat
PALcc, substituted by Asp in SmPAL (Fig. 1), which recognizes the carbonyl group of the
peptide bond linking the amino acid to be amidated to α-hydroxyglycine [41].
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Rat PAL is completely N-glycosylated at a single consensus site located in the loop
connecting β3/β4 in propeller five [48]. Although it is unclear what dictates the efficiency
with which N-glycosylation sites are used [49], it is probable that only two of the four
candidate N-linked glycosylation sites within SmPAL are glycosylated. The most N- and
most C-terminal sites are not included in the β-propeller structure; while both sites may be
accessible, the termination of translation may limit N-glycosylation of the most C-terminal
site. The other two possible sites are in loops and could also be used (Figure 1). The size
increase observed upon secretion of SmPAL may be a result of further post-translational
modifications such as the addition of sialic acid residues or O-linked glycosylation, which
occur at a later stage in protein processing [49].
The conversion of α-N-acetyl-Tyr-Val-α-hydroxyglycine, to α-N-acetyl-Tyr-Val-α-NH2, a
reaction mechanism specific to PAL enzymes, revealed SmPAL catalytic properties within
the range of other eukaryote enzymes. The pH optimum of SmPAL coincides with the
reported characteristics of other PALs [35,44,50,51], and as expected, is less acidic than the
pH optimum of SmPHM [28]. The low pH optimum and high Km (44 μM) of SmPHM,
which deviate from the catalytic properties of the human host enzyme, make SmPHM a
potential novel drug target [28]. Although the functional characteristics of SmPAL revealed
in this study do not display the same degree of divergence from the schistosome host
enzyme as SmPHM [51], it is the degree of structural divergence evident from the
crystallography of rat PALcc [41] which may provide opportunity for chemotherapeutic
intervention. Regardless, the expression of a catalytically active monofunctional SmPAL,
unequivocally confirms the existence of monofunctional amidating enzymes in schistosomes
which act independently of each other, in contrast to the mammalian host enzyme.
Although SmPAL transcript localisation is consistent with the immunolocalisation patterns
of the amidating co-enzyme SmPHM in the schistosome CNS, SmPHM is also localised
extensively in the PNS of adult schistosomes [28]. Although currently there is no molecular
or bioinformatic evidence supporting the possibility of a second SmPAL enzyme, the
enzyme complement of other eukaryotes [24], and the restricted Sm-pal-1 expression pattern
presented here, does not totally diminish the possibility of another active schistosome
amidating lyase. One possible reason for the absence of SmPAL staining in the PNS is that
transcript abundance was below our detection limit. Another reason could be that most of
the PNS cell bodies reside close to the CNS such that transcript does not physically associate
with much of the PNS and as such is identified as CNS staining by in situ hybridisation.
Clearly, more reliable comparisons could be made with immunocytochemical approaches
using a SmPAL antiserum.
The expression of Sm-pal-1 in the CNS of adult schistosomes, coupled with the extensive
immunolocalisation of SmPHM throughout the nervous system of adult schistosomes [28] is
consistent with the hypothesis that SmPAL and SmPHM are neuronally expressed enzymes,
involved in neuropeptide biosynthesis. The widespread localisation of neuropeptide
amidating enzymes in the schistosome nervous system is supported by a recent study which
exploited available transcriptomic and genomic datasets for flatworms, including S.
mansoni, and reported seventeen novel amidated neuropeptides from S. mansoni [13]. A
transcript encoding schistosome NPFF (PQRFamide motif), a peptide similar to vertebrate
neuropeptide FF and not previously reported in invertebrates, was identified, along with
several RFamides, an additional NPF, and novel L/Iamides and PWamides [13]. Thus our
recent bioinformatic data go some way to support and explain the localisation pattern of sm-
pal-1 and the extensive staining patterns reported for SmPHM.
RNAi has quite recently become popular for the functional analysis of schistosome genes
and a growing number of publications report successful gene silencing, of non-neuronal
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transcripts, in larval parasites following dsRNA/siRNA delivery by electroporation and
soaking [31,37,52–64]. Our attempts to knockdown schistosomula Sm-pal-1 gene transcripts
were somewhat less successful than previous publications of schistosomula gene
knockdown. Importantly however, none of the genes previously targeted in schistosomes
have been exclusively involved in neuronal processes, and are most commonly genes such
as the cathepsins B and D, and alkaline phosphatase, which are highly expressed in tissues
relatively more accessible to external dsRNA than neuronal cells [31,37,53,57,60].
In the studies mentioned above, electroporation has been reported to induce >85 %
knockdown of some non-neuronal transcripts in schistosomula [31]. However, in this study
electroporation did not induce measurable gene knockdown of our PAL transcript on either
of two attempts. Some reports detail concentration dependant responses to dsRNA [55,57]
such that it is likely, in the case of Sm-pal-1, that future electroporation experiments may
benefit from the optimisation of dsRNA concentration to produce measurable and consistent
gene silencing.
DsRNA delivery by electroporation is reported to produce much more dramatic gene
suppression (>10 fold) than dsRNA delivery by soaking [31,57]. In this study however,
soaking did successfully and specifically reduce Sm-pal-1 transcript abundance by up to 90
% on two occasions out of six. While these results do indicate that some, if not all,
schistosome neuronal genes are susceptible to RNAi, the question remains as to why
neuronal gene silencing in this case does not appear to be consistently reproducible. Tissue
types are known to differ in their degree of penetrability by dsRNA constructs, resulting in
varying degrees of gene suppression between different tissues [65]. This may present one
possible reason for Sm-pal-1 knockdown unreliability, as dsRNA constructs may have
limited access to deeper tissues such as neuronal cell bodies, where target transcripts are
expressed.
Further, dsRNA delivery by soaking may have proven more successful if larval parasites
were exposed to dsRNA during cercarial transformation. It is thought that schistosome intra-
molluscan life stages are more susceptible to RNAi during transformation when tegumental
membranes are undergoing reorganisation [52]; some reports suggest that this may also be
the case during cercarial transformation [53]. In contrast, other studies involving dsRNA
delivery during cercarial transformation disagree, suggesting that dsRNA uptake is no more
efficient when external membranes are in flux, than when schistosomula are fully formed
[57]. The exploration of alternative dsRNA delivery methods, or the application of smaller
siRNAs may prove beneficial to the induction of neuronal RNAi in schistosomes.
The recent discovery of a rich flatworm neuropeptide complement provides strong support
for the importance of neuropeptide signaling in flatworm neurobiology. One particularly
appealing feature of these discoveries is the fact that the majority of putative neuropeptides
discovered in the flatworm datasets are novel peptides with no obvious homologues in other
animal phyla. Clearly, such differences are a preferred feature of parasite drug targets and
underscore the possibility of exploiting flatworm neuropeptide signaling processes for
parasite control. The mechanisms and processes associated with neuropeptide signaling such
as peptide amidation represent attractive targets for chemotherapeutic intervention. The
presence of a widely expressed PHM enzyme in the nervous system of adult schistosomes
[28], and the identification by this study of a functionally active, monofunctional
schistosome PAL enzyme provides target enzymes for consideration as drug target
candidates. Unfortunately, RNAi has yet to be optimised for neuronally-expressed
transcripts in schistosomes such that validating neuronal gene products as drug targets
remains a challenge. Although we only observed Sm-pal-1 RNAi knockdown intermittently,
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the fact that knockdown occurred on a couple of occasions gives hope that further
optimization of RNAi methods could facilitate robust neuronal RNAi.
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Fig. 1.
ClustalW alignment of schistosome PAL (SmPAL) with the catalytic core of other
eukaryotic PAL domains/proteins. Text boxed in yellow denotes perfectly conserved
residues, text boxed in blue denotes partially conserved residues. Four conserved cysteine
residues are marked by black circles, while four additional SmPAL specific cysteine
residues are highlighted in red. Three conserved His residues involved in binding Zn2+ are
marked by black triangles. Residues in rat PALcc that bind Ca2+ (Val520, Leu587, Asp787)
are not perfectly conserved and are marked by black boxes. Conserved key active site
residues in rat PALcc (Arg533, Tyr654, Arg706) are marked by asterisks. Rat PALcc Met784,
which interacts with the peptide substrate, and is replaced by Asp in SmPAL is marked by a
black rectangle. Four possible SmPAL N-glycosylation sites are highlighted in magenta.
GenBank accession numbers: Rat PAL (RatPALcc, P14925), Human PAL (HsPALcc,
AAA36414), Drosophila melanogaster PAL 1 (dPAL1cc, ACJ13179), Drosophila
melanogaster PAL 2 (dPAL2cc, AAF47043), Lymnaea stagnalis PAL (LsPALcc,
AAD42259), and Caenorhabditis elegans (CePALcc, 172108).
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Fig. 2.
In vitro expression of SmPAL. Western blot analysis of the steady-state distribution of
transfected EGFP (control), dPAL2 and SmPAL. Cell extracts (C; 4% of total amount cell
extract) and spent medium (M; 0.8% of total amount spent medium) are shown; monoclonal
antibody to rhodopsin was used to visualize the transiently expressed proteins. PAL activity
was quantified in aliquots of spent medium; the total amount of activity loaded into the lanes
containing medium is indicated below lanes M4 and M6. The apparent molecular masses of
SmPAL and dPAL2 were compared; Western blot analysis yielded an apparent molecular
mass of 51 kDa for cellular SmPAL (C5) and 59 kDa for secreted SmPAL (M6), dPAL2 is
shown for comparison (C3 and M4). (B) Graph showing analysis of the pH dependence of
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SmPAL activity, indicating optimal activity at pH 4.5, with an additional peak of activity at
pH 6.
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Fig. 3.
Light microscopy images of whole mount in situ hybridisation in adult Schistosoma mansoni
showing Sm-pal-1 gene expression. (A) A female S. mansoni showing Sm-pal-1 localisation
in the cerebral ganglia (CG) and longitudinal nerve cords (LNC). The muscular oral sucker
(OS) and acetabulum (AC) are also labelled. (B) A female worm with Sm-pal-1 gene
expression in the cerebral ganglia (asterisk, *) and LNC running in an anterior and posterior
direction. The oesophagus (OE) and intestinal caecae (IC) are also shown. (C) A female
specimen showing Sm-pal-1 gene expression in the LNCs running parallel to the uterus (U).
(D) The tail of a male S. mansoni showing Sm-pal-1 transcript distribution (arrow heads)
close to the posterior end of the gynaecophoric canal (GC). (E) A S. mansoni negative
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control, treated with Sm-pal-1 sense probes. An adult male and female pair can be seen to
lack Sm-pal-1 staining. The oral sucker (OS), acetabulum (AC) and intestinal caecae (IC) of
the female worm are shown, with the OS of the male positioned below the female anterior
fore-body. Scale bars: A=60 μm; B=20 μm; C=40 μm; D=27 μm; E= 50 μm.
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Figure 4.
The effects of RNA interference on the expression of Schistosoma mansoni PAL (Sm-pal-1)
and S. mansoni alkaline phosphatase (Sm-ap) in larval schistosomula. Representative RT-
PCR results showing marked reduction in Sm-pal-1 transcript levels (~71 %, lane 1)
following treatment with double stranded (ds) RNA for Sm-pal-1. Transcript levels of Sm-ap
are unaffected (lanes 5, 6 and 7). (Lanes: 1, SmPAL-dsRNA treated; 2, SmPHM-dsRNA
treated; 3, untreated (− dsRNA) control; 4, no template control; 5, SmPAL-dsRNA treated;
6, SmPHM-dsRNA treated; 7, - dsRNA control; 8, no template control).
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Table 1
Primer sequences
Primer Name Primer sequence 5′-3′
SmPAL-F1 CGGCACGAGGGAACCAT CATACC
SmPAL-R1 ACTACT ACGTCCCGTTGGT TTAC
SmPAL-Xba1-F TCTAGAAT GTACTTTACATTAATAATC
SmPAL-Bgl2-R AGATCTATAATCGTATTCAA AGTTAAAACG
SmPAL-Nhe1-F GCTAGCATCGTAT ATGATTTCC
SmPAL-Hpa1-R GAATTCGTTAACTCACG CAGG
SmPAL-ISH-T7-F1 TAATACGACTCACTATAGGGCATGTATCGTATATGATTTCC
SmPAL-ISH-R1 GAGATTTAAATCATATGGTCC
SmPAL-ISH-F2 CATGTATCGTATATGATTTCC
SmPAL-ISH-T7-R2 TAATACGACTCACTAT AGGGGAGATTTAAATCATATGGTCC
SmPAL-RNAi-T7-F1 TAATAC GACTCACTATAGGGCATGTATCGTATATGATTTCC
SmPAL-RNAi-R1 GTATTT TCATCCCATACTCG
SmPAL-RNAi-F2 CATGTATCGTATA TGATTTC
SmPAL-RNAi-T7-R2 TAATACGACTCACTATAGGGGTATTTTCATCCC ATACTCG
SmPHM-RNAi-T7-F1 TAATACGACTCACTATAGGGCGTATTCCAGGAGTGACAAC
SmPHM-RNAi-R1 GACTCAGATTCACGACATATAG
SmPHM-RNAi-F2 CGTATTCCAGGAGTGACAAC
SmPHM-RNAi-T7-R2 TAATACGACTCACTATAGGGGACTCAGATTCACGACATATAG
SmPAL-RT S1 GCTTTAAACCTGGTTCAAGC
1322 bp RT-PCR product
SmPAL-RT AS1 ATAATCGTATTCAAAGTTAAAACG
SmAP-RT S1 GCCATCCGACAAGGAATATAAGTGT
98 bp RT-PCR product
SmAP-RT AS1 GGTCCATTGAAAAAGGAGGATATGAGA
T7 RNA polymerase promoter sequences are underlined
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